What's Happening?
Beckman Coulter Diagnostics, a leader in clinical diagnostics, has announced the launch of the Access MeMed BV assay, which has received CE mark approval under the In Vitro Diagnostic Regulation (IVDR). This new assay enables healthcare providers to differentiate
between bacterial and viral infections in approximately 20 minutes. The assay is validated for use with Beckman Coulter's DxI 9000 and Access 2 immunoassay analyzers, allowing for fast and reliable infection differentiation using existing laboratory infrastructure. The collaboration with MeMed, a company specializing in host-response technologies, aims to enhance clinical decision-making and support antimicrobial stewardship initiatives. The assay's rapid results can help reduce unnecessary antibiotic use and improve patient management, as demonstrated by clinical studies and real-world data.
Why It's Important?
The introduction of the Access MeMed BV assay is significant for healthcare systems as it offers a scalable solution to reduce unnecessary hospital admissions and diagnostic testing, potentially saving up to €80 million in avoidable costs across European health systems. By providing rapid differentiation between bacterial and viral infections, the assay supports clinicians in making informed treatment decisions, thereby optimizing antibiotic use and advancing antimicrobial stewardship. This development is crucial in addressing the challenge of antibiotic resistance and improving patient outcomes. The assay's ability to deliver quick results is particularly important in emergency settings where timely treatment decisions are critical.
What's Next?
With the CE mark approval, the Access MeMed BV assay is now available across Europe, and its adoption is expected to grow as healthcare systems seek to improve efficiency and reduce costs. Beckman Coulter Diagnostics plans to continue expanding the availability of the assay, potentially introducing it to other regions. The collaboration with MeMed may lead to further advancements in host-response testing, enhancing the capabilities of clinical laboratories worldwide. As more healthcare providers integrate the assay into their workflows, the impact on patient care and antibiotic stewardship is likely to increase.
